AI in Medicine — Cancer & Rare Disease — 2026-09-24 (Thu) Evening News

Latest news on AI and cancer treatment

Overview

Mainly AI application reports in the diagnostic/imaging field (breast cancer screening, endoscopy, pathology, radiology workflow). Investment and regulatory compliance in drug discovery and molecular design (preclinical stage) and cancer treatment (FDA contract, Ministry of Health, Labor and Welfare budget request) also moved. There is a paucity of primary information showing the specific progress of approval and clinical trials.

Breast cancer

- Breast Cancer Research Foundation opens $100 million venture fund and makes first investment in AI mammography startup

Dealroom

. Stage: Announcement of investment decision, no clinical performance data included. - Report on an AI method that simultaneously reads three layers of biological information (related to subtype diagnosis) in breast cancer

"Bio acting sister r.org"

. Details of what was shown (accuracy/verification method) are not listed in the heading. - Lord's Mark moves AI breast cancer screening technology to final clinical trial stage

Hindustan Times

. Stage: Status announcement of moving to final clinical trial, no result data included.

lung cancer

- Reports of progress in the use of AI using “digital twin” in radiation therapy

"Bio acting sister r.org"

. Details of target cancer types and treatment stages (preclinical/clinical) are not listed in the heading.

Malignant brain tumor

No applicable information

Leukemia/lymphoma

- New AI tool “MANTRA” performs multidimensional analysis of leukemia data and identifies hidden subgroups of patients

"Bio acting sister r.org"

. Stage: Methodology report. The scale of the verification and whether it is prospective/retrospective are not mentioned in the heading.

Colon cancer/digestive organ

- Research showing the possibility of new AI tools to audit quality metrics of colonoscopy

Healthgrades

. Stage: Research report. Details of the study design are not listed in the heading. - AI counts tumor buds on colorectal cancer tissue slides, providing new prognostic indicators

"Bio acting sister r.org"

. Stage: Research report on pathological image analysis. - Alibaba publishes two papers in top journals and releases esophageal cancer screening AI and general-purpose image model

Moomoo

. Stage: This is a paper publication/product release report, and performance values are not listed in the headline.

Rare cancer

No relevant information (The heading "OpenEvidence, Paper2Agent, and AI Won't Replace Clinicians" is not specific to adenoid cystic carcinoma, but only the classification item name, and there is no description of the relevant cancer type in the text)

Diagnosis/Pathology/Image

- Analytical article on how AI is blurring the line between technological development and clinical practice in radiology

STAT

. - Cognita receives contract from FDA for AI radiology report evaluation

Medical Device and Diagnostic Industry

. Stage: Report of FDA contract signing. Details of approval/authorization categories are not listed in the heading. - Essay on incorporating AI into the US military medical system

U.S. Naval Institute

. Specialized content for cancer treatment is not listed in the heading.

Treatment selection/drug discovery

- Tautomer prediction AI tool identifies stable molecules for drug discovery [Genetic Engineering and Biotechnology News]. Stage: Preclinical (molecular design/in silico). - Review article entitled "AI drug discovery revolution" [temaetfs.com]. No description of stages, no mention of individual results. - Reports that virtual cell technology using 4D AI models and "digital twins" accelerates drug discovery

The Medical AI Times

. Stage: Pre-clinical (introduction of technology base). - Anthropic announces that Claude has discovered a new enzyme system similar to CRISPR

"At Usagi. Love."

. Stage: Reporting of in silico discoveries through computational exploration. No description of experimental verification or clinical application stage.

Regulations/Approval

- FDA: Cognita wins contract for AI radiology report evaluation (contract, not approval)

Medical Device and Diagnostic Industry

. - PMDA: No applicable information - EMA: No applicable information

Clinical trial implementation status

No specific data provided regarding individual trial name, phase, and registration status from ClinicalTrials.gov. There are reports that Lord's Mark's breast cancer AI screening technology is "moving to the final clinical trial stage"

Hindustan Times

, No details such as NCT number, phase, target scale, etc.

Japanese movements

- The Ministry of Health, Labor and Welfare requests a budget of more than 196.9 billion yen for drug discovery and advanced medical care, highlighting doubling clinical trials and AI drug discovery as priority areas [Nikkei Biotech ONLINE]. - Report that the British Library is working to become a hub for cutting-edge AI and drug discovery innovation (an example from outside Japan, but introduced in Japanese media)

NewsPicks

. - Report on accelerating drug discovery using 4D AI models and digital twins (Japanese media)

The Medical AI Times

. - Report on Alibaba's esophageal cancer screening AI/general-purpose image model (Japanese media, originating from China) [moomoo.com].

Remarks from VIPs

- Prince Harry (no title listed, speaking as a public figure): warns that AI chatbots could be more dangerous than social media for young people

FOX40

. No direct relationship to cancer treatment is mentioned in the heading. - Other items are not applicable as the list of important persons being tracked is blank.

Latest news on AI and rare and incurable diseases

Overview

Most of the headlines provided are stock/investment-related information (Tempus AI stock trading, Huntington Ingalls Industries stock valuation), and contain little content indicating substantive progress in diagnosis, therapeutic drugs, or systems for rare and intractable diseases. In Japan, there is only one general topic regarding the use of AI by care managers.

Diagnosis of rare diseases

The heading "AI & AI Research Health News: What's Advancing in Healthcare" is only the title and does not provide specific details such as diagnostic accuracy, diagnosis period, number of cases, etc., so there is no information that can be described as progress regarding diagnosis.

Gene analysis/genome

The three headlines regarding Tempus AI (TEM) all report on stock sales by the company's CEO/CAO (transactions based on a pre-set 10b5-1 plan) and stock price fluctuations, and do not state any technical content or clinical results of genetic analysis/genome decoding. Although the company is a genomic medicine company, the headline content is limited to financial and investment information.

Development of therapeutic drugs

No applicable information.

Nerve/muscular diseases

The headline about Huntington Ingalls Industries (HII) is about the stock price evaluation of a shipbuilding business using AI technology, and is a company name (military and shipbuilding company) unrelated to the disease name "Huntington." It does not contain medical information regarding Huntington's disease (designated as an incurable disease, a group of neurological and muscular diseases).

Immunology/Collagen disease

No applicable information.

Rare metabolic/endocrine diseases

No applicable information.

System/Patient Support

No relevant information (The headline ``A story of a care manager who makes full use of AI even though he is not good at ICT'' is general content regarding the use of ICT by nursing care support specialists, and specific references to intractable disease medical expense subsidies, intractable disease methods, research groups, and patient associations cannot be confirmed from the headline.)

Japanese movements

The headline for Care Management Online is the only domestically-originated information, but the content is limited to a general introduction to the use of AI in the work of care managers, and the link to designated intractable disease areas cannot be confirmed from the headline.

Remarks from VIPs

No applicable information.